Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:latanoprostene_bunod
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
S01EE05
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:form |
eye drops
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vyzulta
|
| gptkbp:manufacturer |
gptkb:Bausch_+_Lomb
|
| gptkbp:mechanismOfAction |
prostaglandin analog
nitric oxide donor |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
ophthalmic
|
| gptkbp:sideEffect |
eye pain
eye irritation eye redness increased pigmentation of iris |
| gptkbp:storage |
store at 2°C to 8°C (refrigerated)
|
| gptkbp:usedFor |
ocular hypertension
open-angle glaucoma |
| gptkbp:bfsParent |
gptkb:Bausch_Health_Companies_Inc.
gptkb:Vesneo gptkb:Valeant_Pharmaceuticals_International |
| gptkbp:bfsLayer |
7
|